Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 7998 results

  1. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  2. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  3. New clot-busting drug recommended by NICE set to save NHS £millions

    Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.

  4. More than 40,000 people could benefit after NICE recommends new 'take at home' pill for advanced prostate cancer

    Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.

  5. Interim process and methods statement for bringing together NICE guidance (PMG47)

    This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes

  6. NICE recommends digital technology to help diagnose ADHD in children and young people

    A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.

  7. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)

    NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA987

  8. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

    Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.

  9. NICE and NHS England announce plan to enable innovative tech to be adopted quicker

    NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.

  10. NICE recommended a new gene therapy, transformative cystic fibrosis medicines and an obesity jab, during election period

    More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.

  11. First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK

    More than 700 people set to benefit from new treatment option for advanced lymphoma.

  12. Draft guidance for the potential of new targeted treatment for type of advanced breast cancer

    NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.

  13. NICE publishes final draft guidance on Enhertu after commercial discussions conclude

    NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  14. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

  15. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

    Evidence-based recommendations on selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma in adults.